AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2011
Aug 15, 2011
30751_dirs_2011-08-15_54af9dc9-579d-48fe-9909-21aac4f59281.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: JAZZ PHARMACEUTICALS INC (JAZZ)
CIK: 0001232524
Period of Report: 2011-08-13
Reporting Person: Eller Mark G. (SVP, Research & Clinical Dev.)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-08-13 | Common Stock | M | 690 | — | Acquired | 4151 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-08-13 | Restricted Stock Units | $ | M | 690 | Disposed | Common Stock (690) | Direct |
Footnotes
F1: Represents the conversion upon vesting of restricted stock units into common stock. Such restricted stock units were previously reported in Table II on a Form 3 filed with the Securities and Exchange Commission on February 16, 2011.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock upon the vesting of the unit.
F3: 100% of the restricted stock units vested on August 13, 2011. The common stock into which such vested restricted stock units converted on August 13, 2011 is reported in Table I on this Form 4.